Showing results (31-40 of 252) with videos related to
Sort By:
Pageof 26
Oncology (Williston Park, N.Y.)|January 24, 2006
First-line treatment for advanced non-small-cell lung cancerJanessa J Laskin, Alan B SandlerThe Oncologist|June 5, 2004
Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?Roy S Herbst, Alan B SandlerClinical Advances in Hematology & Oncology : H&O|November 1, 2005
The role of prophylactic cranial radiation in the treatment of non-small-cell lung cancerJanessa J Laskin, Alan B SandlerCancer Investigation|October 1, 2005
State of the art in therapy for non-small cell lung cancerJanessa J Laskin, Alan B SandlerCurrent Oncology Reports|May 16, 2013
EGFR tyrosine kinase inhibitors: difference in efficacy and resistanceKyle W Robinson, Alan B SandlerMedical Hypotheses|September 1, 1983
The sparing interaction of bone mass determinants: a hypothesis with implications for osteoporosisR B Sandler, R E LaPorteJournal of the American Geriatrics Society|March 1, 1981
Quantitative bone assessments: applications and expectationsR B Sandler, D L HerbertClinical Lung Cancer|January 11, 2005
Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancerRoy S Herbst, Alan B SandlerSeminars in Respiratory and Critical Care Medicine|August 10, 2005
Epidermal growth factor receptor inhibitors in lung cancer therapyJanessa J Laskin, Alan B SandlerChaos (Woodbury, N.Y.)|June 5, 2003
The benefits of multibit chaotic sigma delta modulationJ. D. Reiss, M. B. SandlerPageof 26